Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab in Second-line Treatment of Advanced Gastric Cancer: a Prospective, Single Arm Clinical Study (DVES)

NCT05928897 is registered in ClinicalTrials.gov with Xiangya Hospital of Central South University as lead sponsor.

NCT NCT05928897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05928897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab in Second-line Treatment of Advanced Gastric Cancer: a Prospective, Single Arm Clinical Study (DVES)
Lead sponsor
Xiangya Hospital of Central South University
Phase
Phase 2
Overall status
Unknown status
Start date
July 1, 2023
Completion date
July 1, 2025
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer